Abstract 1678P
Background
Breast cancer have a significant impact on the life of married couples. Partners are faced with many challenges such as the heavy treatments and the body changes associated with the disease.
Methods
We conducted a study including patients treated for breast cancer in Salah Azaiz Institute. The aim was to evaluate the impact of cancer on the couple's relationship. The patients agreed to answer a marital adjustment questionnaire (MAQ).
Results
The study included 53 patients with a mean age of 52.25 years, ranging from 34 to 72 years. At the time of the study, 83% (n=44) had been married for between 3 and 60 years, with a mean of 22.5 years and a standard deviation of 11.4. The age at marriage was 27.80±6.9 years, with extremes ranging from 15 to 50 years. Fifteen per cent of patients had no children, and the number of children ranged from 1 to 5, with an average of 2.2. The average age difference between the married women and their partners was 5.3 years, with extremes ranging from one year to 23 years. More than half of the population studied in couple had intimacy problems (n=34),. The mean marital agreement score was 81.65 [41-120]. Eight couples no longer engaged in activities together outside the home and 39.5% (n=21) of them very little. Twenty-nine patients (54.7%) said that they almost never showed affection to their partners. The study of sexual activity showed an abstinence rate of 35.8% (n=19) compared to versus 0% before cancer. A quarter of our population had less than two sexual encounters per month after the disease, compared with 20.8% (n=11) and only 10% had more than 4 intercourses per month compared with 50.9% (n=27), before treatment. Twenty patients (37.3%) frequently disagreed about the sexual relationship. Fifty-four per cent (n=29) of the patients interviewed stated that they had a sexual complaint at the time of the survey: Among them, 32% (n=17) had spoken to their partners about the subject. Twenty-two (n=12) of the patients said they could no longer confide in their partner.
Conclusions
Breast cancer requires adjustments in married life, but with mutual support and open communication, couples can overcome these challenges together.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11